

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 920 869 A1**

(12) **EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:
09.06.1999 Bulletin 1999/23

(51) Int. Cl.⁶: **A61K 31/60**, A61K 47/14,
A61K 47/16, A61K 47/24,
A61K 47/44

(21) Application number: 98928620.8

(22) Date of filing: 23.06.1998

(86) International application number:
PCT/JP98/02780

(87) International publication number:
WO 98/58651 (30.12.1998 Gazette 1998/52)

(84) Designated Contracting States:
BE CH DE DK ES FI FR GB IT LI NL PT

(30) Priority: 25.06.1997 JP 16852297

(71) Applicant:
TEIKOKU SEIYAKU CO., LTD.
Kagawa 769-2695 (JP)

(72) Inventors:
• MIZOBUCHI, Noriko
Kagawa 769-2602 (JP)

- HASEGAWA, Yuichi
Hyogo 675-0063 (JP)
- KAWADA, Mitsuhiro
Kagawa 769-2515 (JP)
- HISAICHI, Shin-ichi, 2050-20, Hikami
Kagawa 761-0612 (JP)

(74) Representative:
Kraus, Walter, Dr.
Kraus & Weisert,
Thomas-Wimmer-Ring 15
80539 München (DE)

(54) **STABLE ASPIRIN-CONTAINING PREPARATIONS FOR EXTERNAL USE**

(57) External preparations containing Aspirin which are stored for a long term and superior in dermal absorbability.

The preparations are prepared by mixing Aspirin together with at least one substance selected from an ester of an organic acid ester having 2 to 20 carbon atoms, a glycerol fatty acid ester, silicon oil, hydrocarbon oil and crotamiton.

EP 0 920 869 A1

Description

Technical Field

- 5 [0001] The present invention relates to a stable external preparation containing Aspirin (acetyl salicylic acid).
 [0002] More specifically, the present invention relates to a technique to store stably an external preparation containing Aspirin for a long term which is characterized in mixing Aspirin together with at least one substance selected from an ester of an organic acid having 2 to 20 carbon atoms, a glycerol fatty acid ester, silicon oil, hydrocarbon oil and crotamiton.

Background Art

- 10 [0003] Aspirin has been used as an anti-inflammatory antipyretic analgesics from of old. It is in general orally administered in form of tablets, granules and so on.
- 15 [0004] However, due to the intestinal injury by Aspirin, its external application has been recently studied. The results are reported in Japanese Patent Pub. No. 3-72426, in Japanese Patent Pub. No. 6-72879, in Japanese Patent Pub. 6-183980, in Japanese Patent Pub. No. (Tokuhyo Hei) 9-503755, etc.
- 20 [0005] These techniques are; one which makes weight on transdermal absorption and does not take care of stability of Aspirin; one which secures stability of Aspirin for a short term, but was not necessarily satisfied for a long term stability; a method characterized in patches to be consumed once and very difficult to apply to preparations consisting of a pack which are often opened and closed, for example creams, solutions, etc.; such a case as in application to preparations, such as ointments, due to the presence of crystals the feeling on use is extremely bad and there is irritation by roughness and therefore, it is very difficult to apply to the region of injured skin like heat injuries. There are many points to be improved in these techniques.
- 25 [0006] Furthermore, there are disclosed techniques of patches containing Aspirin in Japanese Patent Pub. Nos. 8-104624, 8-104625 and 8-113531, but there are not disclosed techniques to stabilize Aspirin in the patches for a long term.
- 30 [0007] The literatures which describe methods for stabilization of Aspirin in preparations except for external preparations, are Japanese Patent Pub. No.56-32425, Japanese Patent Pub. No. 62-89619, Japanese Patent Pub. No. 4-346930 and so on.
- [0008] Because Aspirin is readily hydrolyzed even in the presence of small amount of water and furthermore, by depending on a kind of additives the hydrolysis is accelerated, in these literatures in order to avoid to contact with the additive, it is disclosed to use the protective layer consisting of sucrose, or to use binders in which water was excluded as much as possible and to add a hydrogenated oil as a lubricant. However, it is hardly possible to apply such a technique to external preparations. For example, it is very difficult to make a protective layer between Aspirin and a base in ointments.
- 35 [0009] As such, in external preparations of Aspirin, the technique to avoid water to the possible extent in preparations and store in the package in which water is eliminated as much as possible in order to secure stability of Aspirin in preparing external preparations are found, but the technique to be applied to all external preparations and to secure the satisfied stability has not been shown.
- 40

Disclosure Of Invention

- 45 [0010] The present invention was made in considering of the above problems and the object of the present invention is to provide an external preparation containing Aspirin which is superior in stability and transdermal absorption and can be stored for a long term.
- [0011] That is, by mixing Aspirin together with at least one substance selected from an ester of an organic acid having 2 to 20 carbon atoms, a glycerol fatty acid ester, silicon oil and hydrocarbon oil, it was found to solve the above problems and thus, the present invention was completed.
- 50 [0012] The amount of Aspirin as an active ingredient in an external preparation of the present invention is 0.001 to 30% by weight per total amount, preferably 0.01 to 20% by weight, more preferably 0.05 to 15% by weight. In case of more than 30% by weight of Aspirin, it causes hydrolysis of Aspirin due to increase of stabilization effect by the stabilizing agent. On the other hand, in case of less than 0.001 percent by weight of Aspirin it is hardly to exhibit the pharmacological activities of Aspirin. Each case is not preferable.
- 55 [0013] The stabilizing agents of the present invention are selected from substances having ability to dissolve Aspirin, too and for example, an ester of an organic acid having 2 to 20 carbon atoms, a glycerol fatty acid ester, silicon oil, hydrocarbon oil and crotamiton are used, and in general one substance or more selected from them are used.
- [0014] Examples of the organic acids of esters of organic acids having 2 to 20 carbon atoms are myristic acid, lauric

acid, oleic acid, sebacic acid, palmitic acid, caprylic acid, isooctanoic acid, stearic acid, isostearic acid, acetic acid, propionic acid, isopalmitic acid, undecylic acid, linoleic acid, linolenic acid, adipic acid, salicylic acid, benzoic acid, lactic acid, caproic acid, eicosanic acid, etc., preferably myristic acid, oleic acid, sebacic acid, palmitic acid, isooctanoic acid, isostearic acid and adipic acid, more preferably myristic acid, oleic acid, sebacic acid and adipic acid. Examples of the esters of the organic acids are esters with an aliphatic monoalcohol, such as methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, hexyl ester, octyl ester, decyl ester, cetyl ester, isocetyl ester, stearyl ester, isostearyl ester, oleyl ester, etc.

[0015] Examples of the glycerol fatty acid esters are a plant oil, such as soy bean oil, almond oil, sesame oil, olive oil, camellia oil, corn oil, coconuts oil, etc., an animal oil, such as whale oil, lard, beef tallow, lever oil, etc., triacetin(glycerol triacetate), a middle chain-fatty acid triglyceride, glycerol triisooctanoate, etc., preferably soy bean oil, almond oil, sesame oil, triacetin, a middle chain-fatty acid triglyceride and glycerol triisooctanoate, more preferably soy bean oil, almond oil and a middle chain-fatty acid triglyceride.

[0016] Examples of the hydrocarbon oils are liquid paraffin, squalane, squalene, etc., preferably liquid paraffin and squalane.

[0017] The stabilizing agents of the present invention do not only stabilize Aspirin, but also dissolve Aspirin. Therefore, in mixing the stabilizing agent in external preparations, it has enhancing effect of absorption of Aspirin from skin and it is very preferable.

[0018] The amount of the stabilizing agent is preferably 0.1 to 20 times as much as the amount of Aspirin, more preferably 0.5 to 15 times. In case of less than 0.1 time, Aspirin can not dissolve thoroughly and as a result, transdermal absorption enhancing activity is prohibited. On the other hand in case of more than 20 times irritation against skin etc. occurs. The amount of the stabilizing agent per total weight depends on form of the preparations, but is preferably 0.01 to 50% by weight. When using the stabilizing agent more than 50% by weight in plasters it is difficult to keep their form, and in cataplasms or creams the separation from hydrophilic substances etc. and skin irritation occur and it is not desirable. In case of less than 0.01% by weight especially in the preparation in which water is added, it is difficult to secure stability of Aspirin.

[0019] In order to avoid hydrolysis of Aspirin to the possible extent in the preparation of the present invention, it should be taken care for water contents. For example it is desirable not to add water, or even in case of addition of water the amount of water per total weight is desirably less than 10%, more desirably less than 5%. Within this range the stabilization effect of Aspirin by the stabilizing agent is exhibited and it is possible to avoid hydrolysis of Aspirin. When the amount of water to be added is beyond 10% by weight, the stabilization effect of Aspirin by the stabilization agent is not exhibited enough and hydrolysis of Aspirin is accelerated and therefore, it is not desirable. Kinds of the preparations containing Aspirin of the present invention are not limited if these are usually used as external preparations, such as cataplasms, plasters, ointments, creams, external powders, etc.

[0020] As the other ingredients except for the stabilizing agents of the present invention there can be used ones which are used in ordinal external preparations. However, substances which prohibit stability of Aspirin should be avoided or be used at least.

[0021] In case of cataplasms, Aspirin and the stabilizing agent are added to a following adhesive gel base to prepare cataplasms; an adhesive gel base containing 4 to 20% by weight of a tackifier such as polyacrylic acid, polyacryl acid copolymer, etc., 1 to 5% by weight of a crosslinker, such as aluminum sulfate, aluminum potassium sulfate, aluminum chloride, aluminum magnesium metasilicate, dihydroxyaluminum acetate, etc., 1 to 15% of a viscosity increaser, such as sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, sodium alginate, etc., and 30 to 80% by weight of a polyhydric alcohol, such as glycerin, polyethylene glycol (macrogol), propylene glycol, 1,3-butanediol, etc. Furthermore, in the adhesive gel base there may be mixed a surfactant, such as a polyoxyethylene derivative etc., a perfume, such as l-menthol etc., a preservative, such as a p-hydroxybenzoate etc., small amount of water, etc.

[0022] In case of plasters, Aspirin and the stabilizing agent are added to a following adhesive base material to prepare plasters; an adhesive base material containing 20 to 40% by weight of a tacking agent, such as a styrene-isoprene-styrene block copolymer, an acrylate resin, etc., 25 to 45% by weight of a tackifier resin, such as a cyclic saturated hydrocarbon, a hydrogenated rosin, etc., 5 to 30% by weight of a softening agent, such as liquid gum etc., and 1 to 5% of an antioxidant, such as dibutyl hydroxytoluene etc. And 0.1 to 5% by weight of a high molecular compound being able to contain water, such as polyacrylic acid sodium, polyvinylalcohol, and small amount of water may be added to the above adhesive base material to prepare plaster containing water. Furthermore, a polyhydric alcohol, such as propylene glycol etc., an absorption promoter, such as oleic acid etc., and a surfactant, such as a polyoxyethylene derivative etc. may be mixed to them.

[0023] In case of ointments or creams, Aspirin and the stabilizer are added to 30 to 99.8% by weight of a base, such as white vaseline (petrolatum), yellow vaseline (petrolatum), lanolin, purified bee wax, cetanol, stearyl alcohol, a hydrogenated oil, hydrocarbon gel, polyethylene glycol, etc. to prepare ointments, and further 0.1 to 7% by weight of a surfactant, such as sorbitan sesquioleate, glycerol monostearate, polysorbate 80, etc., and small amount of water are mixed to them to prepare creams. These preparations may contain an antioxidant, such as a tocopherol derivative etc.,

and a preservative, such as a p-hydroxybenzoic acid ester etc.

[0024] In case of external powders, the preparations are prepared by mixing 50 to 99.8% by weight of a filler, such as potato starch, rice starch, corn starch, talc, zinc oxide, etc. with Aspirin and the stabilizing agent.

[0025] The external preparations containing Aspirin of the present invention are prepared according to the conventional methods of external preparations. For example, ointments are prepared by melting a base and the stabilizing agent under warming, mixing them homogeneously and, if necessary adding an additive, such as an antioxidant, a preservative, a surfactant, purified water, etc., and then, adding powdered Aspirin under stirring.

[0026] Cataplasms are prepared by dissolving a tackifier, such as polyacrylic acid etc. and a viscosity increaser in a polyhydric alcohol, such as glycerin etc. by heating, adding Aspirin, the stabilizing agent and another additive after cooling, mixing them homogeneously and then adding a crosslinker to prepare adhesive gel bases. Then, by spreading the bases thus obtained on adequate support like felt and cutting it in desired size, there are prepared cataplasms.

[0027] The plasters are prepared as follows; by mixing a tacking agent, such as acrylate etc., a tackifier resin, such as a hydrogenated rosin, etc., a softener, such as liquid gum etc. and, if desired an antioxidant under stirring and by heating; and adding a mixture of Aspirin and a stabilizing agent prepared separately and kneading; and then spreading on release paper; and after drying laminating with a soft support, such as polyurethane film, polyethylene film, vinyl chloride film, woven textile, felt, etc.; and cutting it in desired size.

Explanation of Figures

[0028]

Figure 1. shows the activity of ointments containing Aspirin against dermal coloboma of rats.

Best Mode for Carrying Out the Invention

[0029] The present invention is shown in more detail by the following examples. But the present invention is not limited by the examples.

Example 1 to 7 (ointments)

[0030] According to the ingredients shown in Table 1, white vaseline or hydrocarbon gel and a stabilizing agent(s) were melted under warming on a water bath. Thereto Aspirin was added and the mixture was well stirred to disperse Aspirin and further cooled under stirring to prepare ointments. In this procedure there are used machines, such as a vacuum emulsifier (T.K.ROBO MIXER prepared by Tokusyukika Kogyo), a grinder, a planetary mixer, etc.

Table 1

Ingredients of ointments containing Aspirin							
Example	1	2	3	4	5	6	7
Ingredient	ingredient ratio (% by weight)						
White vaseline	97	94	98.4				50
Hydrocarbon gel				94.5	96	60	49.8
Aspirin	0.5	5	0.1	0.5	0.5	15	0.01
Isopropyl myristate				2.5	1	25	
Squalane			1.5				
Sesame oil	2.5						
Silicon oil		1					
Crotamiton				2.5	2.5		0.19

Examples 8-14 (Creams)

[0031] According to the ingredients shown in Table 2, white vaseline, yellow vaseline or hydrocarbon gel and a stabilizing agent(s) were melted under warming on a water bath. Thereto Aspirin was added and the mixture was well stirred

to disperse Aspirin. On the other hand a surfactant was added to purified water and the solution was stirred well. This solution was added to the dispersion containing Aspirin prepared above. The mixture was stirred and cooled to prepare creams. In this procedure a vacuum emulsifier (T.K.ROBO MIXER prepared by Tokusyukika Kogyo) was used.

Table 2

Ingredients of creams containing Aspirin							
Example	8	9	10	11	12	13	14
Ingredient	ingredient ratio (% by weight)						
Hydrocarbon gel		59					
White vaseline	85		30	40	35	97.45	45
Yellow vaseline			24				
Cetanol							10
Aspirin	0.5	5	2	5	5	0.5	5
Isopropyl myristate	10	30					
Glycerin trioctanoate			40	45	45	0.05	30
Polysorbate 80	0.5	1					
Glycerin monostearate			2	5	5	1	
Sorbitan sesquioleate							5
Purified water	4	5	2	5	10	1	5

Example 15 - 20 (Plasters)

[0032] According to ingredients shown in Table 3, a styrene-isoprene-styrene block copolymer, a cyclic saturated hydrocarbon resin, a liquid gum (polybutene, polyisoprene gum), an antioxidant (dibutylhydroxytoluene), or liquid paraffin was put in a warmed kneader and melted under heating with stirring. On the other hand, Aspirin, isopropyl myristate and a hydrogenated rosin glycerin ester were mixed and stirred and the mixture was added to the mixture prepared previously and kneaded well under stirring. In cases of Examples 15 to 18, adhesives prepared thus, were spread on an appropriate support and cut in desired size to prepare plasters containing Aspirin. In cases of Examples 19 and 20, sodium polyacrylate was dissolved in warmed purified water under stirring. This solution was added to oil tackifiers prepared above and the mixture was stirred homogeneously, and then were spread on an appropriate support and cut in desired size to prepare plasters containing Aspirin.

Table 3

Ingredients of plasters containing Aspirin						
Example	15	16	17	18	19	20
Ingredient	ingredient ratio (% by weight)					
Aspirin	2.5	10	15	5	5	5
stylenoisoprenestyrene block copolymer	30	30	25	35	25	30
hydrogenated rosin glycerin ester		40	40	40		
Polybutene		9		5		
Polyisoprene gum	10		10			
Dibutyl hydroxytoluene	1	1	1	1		
Liquid paraffin	10				15	20
Isopropyl myristate	5	10	9	14	10	15

Table 3 (continued)

Ingredients of plasters containing Aspirin						
Example	15	16	17	18	19	20
Ingredient	ingredient ratio (% by weight)					
cyclic saturated hydrocarbon	41.5				38.5	27.5
Sodium polyacrylate						0.5
Polyvinyl alcohol					1.5	
Purified water					5	2

Examples 21 to 27 (Cataplasms)

[0033] Polyacrylic acid and polyvinylpyrrolidone were dispersed and then dissolved in propylene glycol, Macrogol 200, Macrogol 400, or 1,3-butanediol under warming. Separately, Aspirin was dispersed and dissolved in isopropyl myristate, crotamiton, or castor oil and this solution was added to the base solution prepared above and kneaded and then, thereto aluminium magnesium metesilicate or polysorbate 80 was added and kneaded. The resulting adhesive was spread on an appropriate support like felt to prepare cataplasms containing Aspirin.

Table 4

Ingredients of cataplasms containing Aspirin							
Example	21	22	23	24	25	26	27
Ingredient	ingredient ratio (% by weight)						
Aspirin	5	1	10	0.5	0.1	25	5
Isopropyl myristate	10	4	10	4.5	0.4		5
Crotamiton		5	5	5	0.5	5	
Polyacrylic acid	15	15	5	10	9	10	10
Glycerin	20	20	13	40	10	12	23
Propyleneglycol	30	30	20		20		
Macrogol 200		5		25	20		
Macrogol 400	10	10		10		10	25
1,4-Butanediol			10		27.5	15	
aluminum magnesium metesilicate	3	3	2	1	2	3	2
Polyvinyl pyrrolidone	5	5	10	3	10	5	5
Castor oil			10				10
Polysorbate 80	2	2	5	1	0.5	5	5

Examples 28 to 32 (external powders)

[0034] Aspirin and isopropyl myristate, soy bean oil, or liquid paraffin were mixed well and the mixture was added to potato starch, corn starch, talc or zinc oxide and to mix homogeneously. There were thus obtained external powders containing Aspirin.

Table 5

Ingredients of external powders containing Aspirin					
Example	28	29	30	31	32
Ingredient	ingredient ratio (% by weight)				
Aspirin	5	20	0.50	0.5	25
Isopropyl myristate	5		2.5		5
Soybean oil		10			5
Liquid paraffin				4.5	5
Potato starch	30			25	30
Corn starch	20	30	47		
Talc	40	40		50	30
Zinc oxide			50	20	

Comparative Example 1.

[0035] According to the ingredients shown in below, white vaseline and isostearic acid were melted under warming on a water bath. Thereto Aspirin was added and the mixture was stirred to disperse well and cooled to prepare an ointment. In this procedure a vacuum emulsifier (T.K.ROBO MIXER prepared by Tokusyukika Kogyo) was used.

Ingredients	Contents
Aspirin	0.5g
White vaseline	97.0g
Isostearic acid	2.5g

Comparative Example 2

[0036] According to the method and ingredients described in Comparative Example 1 except for oleyl alcohol instead for isostearic acid to prepare an ointment.

Comparative Example 3

[0037] According to the method and ingredients described in Comparative Example 1 except for benzyl alcohol instead for isostearic acid to prepare an ointment.

Comparative Example 4

[0038] According to the following ingredients, Aspirin was dissolved in a small amount of ethanol and the solvent was distilled off to prepare fine powders. Thereto were added polysorbate 80 and hydrocarbon gel and the mixture was mixed homogeneously to prepare an ointment.

Ingredients	Contents
Aspirin	0.5g
Hydrocarbon gel (Japanese Pharmaceutical Excipients)	94.5g

(continued)

Ingredients	Contents
Polysorbate 80	5.0g

Comparative Example 5

[0039] According to the following ingredients, Aspirin, hydrocarbon gel and carnauba wax were mixed homogeneously to prepare an ointment.

Ingredients	Contents
Aspirin	0.5g
Hydrocarbon gel (Japanese Pharmaceutical Excipients)	98.5g
Carnauba wax	5.0g

Experiment 1

[0040] The ointments of present invention prepared based on prescriptions 1 to 42 shown in Tables 6 - 8, and the ointments prepared by Comparative Examples 1 to 4 were tested on stability in storage at 75% RH at 40°C, and at 50°C. Test samples were stored under each condition for one or two months, and after sampling, contents of Aspirin remaining in each sample was measured and the remaining percentage per initial content was calculated and shown in Table 9 - 10.

[0041] As shown in Tables 9 and 10, when preparations of Comparative Examples were stored for 2 months at 40°C and 50°C, in case of the former, at least about 20% of Aspirin was decomposed and in case of the latter almost of Aspirin was decomposed. On the contrast when preparations containing the stabilizing agent of the present invention were stored at the same conditions, at least 93% of Aspirin remains at 40°C and about 70% of Aspirin remains even at 50°C. Accordingly, it is found that preparations of the present invention show excellent stability effect to Aspirin in comparison with preparations of Comparative Examples.

Experiment 2

[0042] The cream prepared by example 14, the plasters prepared by Examples 16 and 18, and the external powder prepared by Example 29 were tested on stability in storage at 75% RH at 40°C in the same manner as Experiment 1. Content of Aspirin was measured and the results were shown in Table 11.

Experiment 3.

[0043] By using the ointments of the present invention prepared based on prescriptions No. 18, 20, 25, 27, 28, 30, 32, 33, 34, 35, 36, 37, 39, 40 and 41 shown in Tables 6 to 8, and the ointments prepared by Comparative Examples 4 and 5, in vitro skin-permeability test was carried out. Abdominal skin of Wistar rat (6 weeks old) was taken out and after removal of its subcutaneous fat was fixed on a Frantsu type expansion cell (cell volume of a receiver: 10cm³, effective expansion surface area: 2.27cm²). A phosphate buffer solution (pH 7.2) was filled in the receiver and ointments (100mg) were spread on the side of the corium. Four, 8 and 24 hours after the spread, the solution in the receiver was taken and amounts of Aspirin and salicylic acid in it were measured. The amount of salicylic acid was calculated into amount of Aspirin. Both amounts were combined and divided by the amount of Aspirin contained in the ointment and multiplied by 100 and its values were shown in Table 12.

[0044] As shown in Table 12, in cases of the preparations of Comparative Examples maximum skin permeation rate was at most about 20%, but in case of the ointment of the present invention using a stabilizing agent(s), its permeation rate was at least 20% and in some cases more than 70% and therefore, the ointment of the present invention is superior to that of the Comparative Example in the skin permeation.

Experiment 4

[0045] The activity of ointments containing Aspirin on the skin injured rats.

[0046] A group consisting of 6 Wistar rats (400 - 450g) was used. After removal of hairs on back on the rat, the back sterilized by Isodine® (povidone-iodine) and the skin of the back was punched out by a round punch (inner diameter: 12mm) under anesthesia by ether to make two parts of injuries symmetrically with respect to mesad. From one day after making the injuries ointments prepared based on prescriptions 1, 18, 30, 31, 31 and 40 were applied to the injuries 0.2g per injury part once a day for 14 days. The control group was not treated. The judgement of the effect was done as follows: The major axis and the minor axis on the injury were measured and calculate the area and change of the areas was calculated by the following formula to prepare a curve of the area changing. The area under the thus obtained curve was calculated and its value was as index (therapeutic index). The result was shown in Figure 1.

[0047] As is clear from Figure 1, it is shown that the ointment using a stabilizing agent of the present invention shows therapeutic effect against skin injury of rats.

$$\text{Change of the area} = \frac{[\text{major axis} \times \text{minor axis of the injury on the observation date}]}{[\text{major axis} \times \text{minor axis of a injury on one day after preparing the injury}]} \times 100$$

Table 6

Prescription of ointments containing Aspirin							
Example of prescription	1	2	3	4	5	6	7
Ingredients	ratio of ingredients(% by weight)						
White vaseline	97	97	97	97	97	97	97
Aspirin	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Diethyl sebacinate	2.5						
Myristyl myristate		2.5					
Cetyl parmitate			2.5				
Isopropyl myristate				2.5			
Glycerol triisooctanoate					2.5		
Isostearyl palmitate						2.5	
Oleyl oleate							2.5
Example of prescription	8	9	10	11	12	13	14
Ingredients	ratio of ingredients(% by weight)						
White vaseline	97	97	97	97	97	97	97
Aspirin	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Cetyl isooctanoate	2.5						
Isocetyl isostearate		2.5					
Isopropyl parmtate			2.5				
Octyldodecyl myristate				2.5			
Squalane					2.5		
Soybean oil						2.5	
Sesame oil							2.5

Table 7

Prescription of ointments containing Aspirin							
Example of prescription	15	16	17	18	19	20	21
Ingredients	ratio of ingredients(% by weight)						
White vaseline	97	97	97	97	97	97	97
Aspirin	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Sweet almond oil	2.5						
Silicon oil		2.5					
Liquid palaffin			2.5				
Crotamiton				2.5			
middle chain-fatty acid triglyceride					2.5		
Diisopropyl adipinate						2.5	
Triacetin							2.5
Example of prescription	22	23	24	25	26	27	28
Ingredients	ratio of ingredients(% by weight)						
White vaseline	97	97	97				
Hydrocarbon gel				98.5	98	97.5	97
Aspirin	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Diisopropyl cebacinate	2.5						
n-Butyl acetate		2.5					
Hexyl laurate			2.5				
Crotamiton				1	1.5	2.0	2.5

Table 8

Prescription of ointments containing Aspirin							
Example of prescription	29	30	31	32	33	34	35
Ingredients	ratio of ingredients(% by weight)						
Hydrocarbon gel	97	94.5	94.5	94.5	94.5	94.5	94.5
Aspirin	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Isopropyl myristate	2.5						
Crotamiton		5					
Isopropyl myristate			5				
Oleyl oleate				5			
Diisopropyl cebacinate					5		
Diisopropyl adipinate						5	
middle chain-fatty acid triglyceride							5
Example of prescription	36	37	38	39	40	41	42
Ingredients	ratio of ingredients(% by weight)						
Hydrocarbon gel	94.5	94.5	94.5	94.5	94.5	94.5	94.5
Aspirin	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Octyldodecyl myristate	5						
Sesame oil		5					
Soybean oil			5				
Squalane				5			
Glycerol trioctanoate					5		
Isopropyl myristate						1	2.5
Crotamiton						2.5	2.5

Table 9

Test results on stability of ointments containing Aspirin						
Prescription	40°C 75% RH			50°C 75% RH		
	Remain ratio(%)					
	Initial	1 month	2 month	Initial	1 month	2 month
1	100	96.0	93.8	100	90.7	81.9
2	100	99.6	99.3	100	98.4	97.6
3	100	98.4	97.5	100	95.6	93.3
4	100	98.5	96.4	100	95.6	86.1
5	100	99.0	98.9	100	97.5	95.6
6	100	98.3	94.0	100	95.3	89.8

EP 0 920 869 A1

Table 9 (continued)

Test results on stability of ointments containing Aspirin						
Prescription	40°C 75% RH			50°C 75% RH		
	Remain ratio(%)					
	Initial	1 month	2 month	Initial	1 month	2 month
7	100	98.6	98.0	100	94.6	81.0
8	100	99.8	99.6	100	97.5	96.4
9	100	99.0	98.6	100	96.3	92.5
10	100	99.2	98.8	100	94.9	91.9
11	100	98.6	97.9	100	93.4	91.0
12	100	99.5	99.3	100	98.0	96.2
13	100	99.6	98.2	100	96.2	92.3
14	100	99.8	98.6	100	98.5	97.5
15	100	98.5	96.7	100	96.0	90.0
16	100	99.5	99.0	100	99.1	97.7
17	100	99.1	99.0	100	98.3	96.8
18	100	97.5	94.8	100	88.1	80.7
19	100	99.7	99.4	100	98.3	97.2
20	100	99.6	99.6	100	96.7	95.1
21	100	93.5	88.9	100	88.3	71.6
22	100	99.4	98.5	100	98.0	95.6
23	100	99.5	98.7	100	96.8	95.1
24	100	99.0	97.3	100	95.8	93.3

Table 10

Test results on stability of ointments containing Aspirin						
Prescription	40°C 75% RH			50°C 75% RH		
	Remain ratio(%)					
	Initial	1 month	2 month	Initial	1 month	2 month
25	100	98.1	97.4	100	90.1	89.0
26	100	97.1	93.4	100	96.5	89.9
27	100	96.3	93.9	100	84.4	78.3
28	100	97.4	95.9	100	94.4	84.6
29	100	99.2	99.2	100	98.8	96.6
30	100	94.6	90.0	100	88.5	79.1
31	100	98.7	95.9	100	95.4	93.6
32	100	98.7	97.0	100	96.1	94.9
33	100	97.9	96.8	100	93.5	90.7
34	100	99.3	98.8	100	94.5	89.3

Table 10 (continued)

Test results on stability of ointments containing Aspirin						
Prescription	40°C 75% RH			50°C 75% RH		
	Remain ratio(%)					
	Initial	1 month	2 month	Initial	1 month	2 month
35	100	100.0	99.8	100	96.5	94.8
36	100	99.9	97.0	100	96.6	93.9
37	100	98.4	97.9	100	96.1	94.2
38	100	99.0	97.6	100	94.7	93.1
39	100	99.0	98.2	100	97.2	95.6
40	100	99.2	98.2	100	96.7	94.5
41	100	97.7	96.6	100	90.8	86.5
42	100	96.3	93.8	100	87.2	82.7
Comp Ex. 1	100	84.9	80.8	100	80.7	54.7
Com. Ex. 2	100	66.1	46.0	100	1.1	0
Com. Ex. 3	100	61.4	28.5	100	2.8	0
Com. Ex. 4	100	20.4	11.4	100	0	0

Table 11

The test results on stability of preparations containing Aspirin			
	Remain ratio of (%)		
	Initial	1 month	2 month
Example 14 (cream)	100	89.1	74.7
Example 16 (plaster)	100	94.3	90.2
Example 18 (plaster)	100	89.3	79.3
Example 29 (external powder)	100	96.6	90.1

Table 12

The results of measurement on in vitro skin permeability of Aspirin			
Prescription No.	4 hours later	8 hours later	24hours later
	Permeability (%)		
18	5.8	12.2	24.7
20	0.7	6.6	23.4
25	7.9	14.9	33.4
27	10.7	20.4	42.8
28	14.5	26.7	53.6

Table 12 (continued)

The results of measurement on in vitro skin permeability of Aspirin			
Prescription No.	4 hours later	8 hours later	24hours later
	Permeability (%)		
30	4.7	11.6	36.4
32	7.8	13.4	44.9
33	7.7	15.8	47.3
34	3.8	10.9	34.6
35	5.2	6.3	28.4
36	3.9	15.4	37.6
37	2.5	5.9	24.0
39	3.6	9.4	30.0
40	16.7	30.9	70.8
41	16.9	27.5	59.5
Comp. Ex.4	1.3	4.5	19.3
Comp. Ex.5	0.7	3.1	11.8


Industrial Applicability

[0048] The external preparations of the present invention containing Aspirin can reserve stably Aspirin for a long term and is superior in transdermal absorption of Aspirin from skin.

Claims

1. An stable external preparation containing Aspirin which is characterized in mixing Aspirin together with at least one substance selected from an ester of an organic acid having 2 to 20 carbon atoms, a glycerol fatty acid ester, silicon oil, hydrocarbon oil and crotamiton.
2. The stable external preparation of claim 1 wherein the ester of an organic acid is an ester of myristic acid, lauric acid, oleic acid, sebacic acid, palmitic acid, isooctanoic acid, isostearic acid, acetic acid or adipic acid.
3. The stable external preparation claim 1 wherein the ester of an organic acid is an ester of myristic acid, oleic acid, sebacic acid, palmitic acid, isooctanoic acid, , isostearic acid or adipic acid.
4. The stable external preparation wherein the esters of an organic acid are esters of myristic acid, oleic acid, sebacic acid and adipic acid.
5. The stable external preparation claim 1 wherein the glycerol fatty acid ester is soy bean oil, almond oil, sesame oil, triacetin, a middle chain-fatty acid triglyceride or glycerol triisooctanoic acid.
6. The stable external preparation of claim 1 wherein the glycerol fatty acid ester is soy bean oil, almond oil, sesame oil or a middle chain-fatty acid triglyceride.
7. The stable external preparation of claim 1 wherein the hydrocarbon oil is liquid paraffin or squalane.

Figure 1



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/02780

A. CLASSIFICATION OF SUBJECT MATTER				
Int.Cl. ⁶ A61K31/60, A61K47/14, A61K47/16, 161K47/24, A61K47/44				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols)				
Int.Cl. ⁶ A61K31/60, A61K47/14, A61K47/16, 161K47/24, A61K47/44				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)				
CA (STN)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	JP, 3-72426, A (Teikoku Seiyaku Co., Ltd.), 27 March, 1991 (27. 03. 91), Claims ; page 2, upper right column, line 4 to lower left column, line 16 ; Examples (Family: none)	1-7		
X	JP, 5-246892, A (Pola Chemical Industries Inc., Toko Yakuhin Kogyo Co., Ltd.), 24 September, 1993 (24. 09. 93), Claims ; page 3, left column, lines 21 to 31 (Family: none)	1-7		
X	JP, 8-208487, A (Sekisui Chemical Co., Ltd.), 13 August, 1996 (13. 08. 96), Claims ; page 3, left column, lines 10 to 36 ; Examples (Family: none)	1-7		
X	Masatoshi Tsuchiya, "Preparation of Stable Hydrophilic Aspirin Ointment (in Japanese)", Journal of the Nippon Hospital Pharmacists Association, Vol. 20, No. 6 (1994), p.502-508	1-7		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search 31 August, 1998 (31. 08. 98)		Date of mailing of the international search report 8 September, 1998 (08. 09. 98)		
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer		
Facsimile No.		Telephone No.		

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/02780

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP, 53-101539, A (The Procter & Gamble Co.), 5 September, 1978 (05. 09. 78), Page 5, upper right column, line 15 to page 7, lower left column, line 4 & GB, 1594628, A & DE, 2755224, A	1-7
Y	JP, 5-229949, A (Zeria Pharmaceutical Co., Ltd.), 7 September, 1993 (07. 09. 93), Claims ; page 2, left column, line 42 to right column, line 4 ; Examples (Family: none)	1
PX	JP, 10-45599, A (Luitpold Pharma GmbH.), 17 February, 1998 (17. 02. 98), Claims ; Examples & EP, 803254, A1	1-4

Form PCT/ISA/210 (continuation of second sheet) (July 1992)